Receive Our Newsletter

Octapharma USA Announces FDA Approval of NUWIQ New Product Strengths


Note: The following is an edited version of a press release from Octapharma USA. Read the press release from Octapharma USA in it’s entirety here.

Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved new product strengths for NUWIQ. The agency approved new single dose NUWIQ vial strengths of 2500, 3000 and 4000 International Units (IU), which will be available for ordering in the U.S. starting September 2017.

Comments (No comments)

Assisting and Advocating for the Bleeding Disorders Community